An All-Oral Combination Study of AB-506 and AB-452
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs AB-452 (Primary) ; AB-506 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- 03 Oct 2019 Status changed from planning to withdrawn prior to enrolment, according to an Arbutus Biopharma media release.
- 13 Jul 2018 New trial record
- 10 Jul 2018 According to an Arbutus Biopharma media release, the company expects to initiate this trial in 2H 2019.